Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Sandoz Enbrel Ruling Leads Company To Chop Asset

 
• By Dean Rudge
  
Invest
Coherus will invest R&D dollars into oncology and immuno-oncology • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products